Bionutrics snares Kirk for $12M

Generic drug developer Bionutrics is buying Kirk Pharmaceuticals for $12 million in cash and debt. Ronald H. Lane, PhD, Bionutrics' chairman and CEO, said, "This acquisition is an important step in the commercialization of Bionutrics' drug technology and further execution of our business plan. Kirk has relationships with some of the world's largest drug retailers and generic pharmaceutical companies and a growing manufacturing presence in the industry."

- read this press release for more